Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti-CD20 Therapy”

137 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 137 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07729826
What this trial is testing

C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

Who this might be right for
Lupus Nephritis (LN)Systemic Lupus Erythematosus (SLE)Autoimmune Diseases
AbelZeta Inc. 50
Not applicableEnded earlyNCT01083563
What this trial is testing

Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy

Who this might be right for
Rheumatoid Arthritis
University of Rochester 7
Testing effectiveness (Phase 2)Study completedNCT00346684
What this trial is testing

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Who this might be right for
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
University of Cologne
Testing effectiveness (Phase 2)Study completedNCT00029107
What this trial is testing

Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis

Who this might be right for
Hepatitis CVasculitis
National Institute of Allergy and Infectious Diseases (NIAID) 47
Post-approval studies (Phase 4)Looking for participantsNCT07609719
What this trial is testing

Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Who this might be right for
Multiple Sclerosis
Genentech, Inc. 100
Early research (Phase 1)Enrolling By InvitationNCT07038447
What this trial is testing

KITE-363 in Participants With Refractory Autoimmune Diseases

Who this might be right for
Systemic Lupus ErythematosusLupus NephritisSystemic Sclerosis+1 more
Kite, A Gilead Company 52
Early research (Phase 1)Ended earlyNCT04160195
What this trial is testing

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Non-hodgkinsChronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI) 2
Early research (Phase 1)Active Not RecruitingNCT05797233
What this trial is testing

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic LeukemiaLymphoma, B-Cell
National Cancer Institute (NCI) 58
Testing effectiveness (Phase 2)Ended earlyNCT00072449
What this trial is testing

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Who this might be right for
Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Study completedNCT00936546
What this trial is testing

A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

Who this might be right for
Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
University Hospital, Ghent 3
Testing effectiveness (Phase 2)Study completedNCT00285428
What this trial is testing

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Gilead Sciences 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT07480863
What this trial is testing

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Who this might be right for
Marginal Zone Lymphoma(MZL)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 65
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Large-scale testing (Phase 3)Study completedNCT00004179
What this trial is testing

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC 475
Testing effectiveness (Phase 2)Study completedNCT04893096
What this trial is testing

MOR202 for Refractory MN

Who this might be right for
Membranous Nephropathy
Mario Negri Institute for Pharmacological Research 10
Early research (Phase 1)Looking for participantsNCT05668403
What this trial is testing

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Who this might be right for
Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd 52
Testing effectiveness (Phase 2)WithdrawnNCT00004039
What this trial is testing

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Ended earlyNCT01390545
What this trial is testing

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Who this might be right for
Rheumatoid Arthritis
Takeda 300
Testing effectiveness (Phase 2)Study completedNCT00071955
What this trial is testing

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Genitope Corporation
Testing effectiveness (Phase 2)UnknownNCT00293475
What this trial is testing

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Who this might be right for
Central Nervous System Lymphoma
OHSU Knight Cancer Institute 81
Next Page